DelveInsight’s Seborrhoeic Dermatitis pipeline report provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
Some of the Key Highlights from the Seborrhoeic Dermatitis Pipeline Report
There are currently 5+ drugs in the Seborrhoeic Dermatitis pipeline.
The Seborrhoeic Dermatitis pipeline comprises therapies in different clinical phase stages, including ARQ-154, DBI-002, PAC 14028, MSB-7154, and others.
Some of the companies actively working to improve the Seborrhoeic Dermatitis treatment landscape are Arcutis Biotherapeutics, Inc., DermBiont, Amorepacific, MatriSys Bio, and others.
Seborrhoeic Dermatitis pipeline therapies that are in the late stage of development include ARQ-154 (Arcutis Biotherapeutics), DBI-002 (DermBiont), PAC 14028 (Amorepacific), along with others.
MSB-7154 is being developed and investigated in the preclinical stage by MatriSys Bio.
Get a detailed analysis of the pipeline landscape @ Seborrhoeic Dermatitis Pipeline Analysis
Seborrhoeic Dermatitis Overview
Seborrhoeic Dermatitis, also known as seborrhoea, is a chronic skin condition. It is a skin condition distinguished by scaly patches and red skin, most notably on the scalp. Seborrhoea can also occur on oily body parts such as the face, sides of the nose, brows, ears, eyelids, upper chest, and back. Seborrhoeic dermatitis can cause stubborn dandruff in addition to scaly patches and red skin.
Seborrhoeic Dermatitis Symptoms
Seborrheic Dermatitis symptoms include:
Dandruff (skin flakes) on your scalp, hair, brows, beard, or mustache
Patches of greasy skin with flaky white or yellow scales or crust on the scalp, face, sides of the nose, brows, ears, eyelids, chest, armpits, groin area, or under the breasts.
Red skin
Itching
Seborrhoeic Dermatitis Treatment
The main options for Seborrheic Dermatitis treatments are medicated shampoos, creams, and lotions. Before turning to prescription medications, dermatologists advise patients to try home remedies first, such as over-the-counter dandruff shampoos.
Seborrhoeic Dermatitis Pipeline Analysis: Drug Profiles
ARQ-154: Arcutis Biotherapeutics, Inc.
Product Description
ARQ-154, or topical roflumilast foam, is a foam formulation of a highly potent and selective PDE4 inhibitor (roflumilast). Roflumilast has been licensed by the US Food and Drug Administration (FDA) for systemic use to lower the risk of COPD exacerbations since 2011.
Phase III
NCT04973228: Arcutis Biotherapeutics, Inc. began a randomized, Phase III trial in July 2021 to assess the efficacy and safety of ARQ-154 Foam 0.3 percent Administered QD in subjects with Seborrheic Dermatitis.
Seborrhoeic Dermatitis Pipeline Therapies and Key Companies
DBI-002: DermBiont
PAC 14028: Amorepacific
MSB-7154: MatriSys Bio
Find out the emerging therapies and companies @ Seborrhoeic Dermatitis Treatment
Seborrhoeic Dermatitis Therapeutics Assessment
By Product Type
Monotherapy
Combination Therapy
By Stage
Discovery
Pre-Clinical
Phase I
Phase II
Pre-registration
By Route of Administration
Inhalation
Intravenous
Oral
Subcutaneous
By Molecule Type
Small Molecule
Stem Cell Therapy
Gene Therapy
Targets
Immune System
Multiple Kinase
By Mechanism of Action
Protease Inhibitors
Immunomodulatory
Scope of the Report
Coverage: Global
Seborrhoeic Dermatitis Key Players: Arcutis Biotherapeutics, Inc., DermBiont, Amorepacific, MatriSys Bio, among others
Seborrhoeic Dermatitis Pipeline Therapies: ARQ-154, DBI-002, PAC 14028, MSB-7154, and others
Table of Contents
1.
Introduction
2.
Executive Summary
3.
Seborrhoeic Dermatitis: Overview
4.
Seborrhoeic Dermatitis- Analytical Perspective In-depth Commercial Assessment
5.
Seborrhoeic Dermatitis Pipeline Therapeutics
6.
Seborrhoeic Dermatitis Late Stage Products (Phase III)
7.
Seborrhoeic Dermatitis Mid Stage Products (Phase II)
8.
Seborrhoeic Dermatitis Early Stage Products (Phase I)
9.
Seborrhoeic Dermatitis Preclinical Products
10.
Seborrhoeic Dermatitis Therapeutic Assessment
11.
Seborrhoeic Dermatitis Inactive Products
12.
Seborrhoeic Dermatitis Company-University Collaborations (Licensing/Partnering) Analysis
13.
Seborrhoeic Dermatitis Key Companies
14.
Seborrhoeic Dermatitis Key Products
15.
Seborrhoeic Dermatitis- Unmet Needs
16.
Seborrhoeic Dermatitis- Market Drivers and Barriers
17.
Seborrhoeic Dermatitis- Future Perspectives and Conclusion
18.
Seborrhoeic Dermatitis Analyst Views
19.
Appendix
20.
About DelveInsight
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts
Key questions answered in the Seborrhoeic Dermatitis Pipeline Report
What treatments are available for seborrhoeic dermatitis?
How many pharmaceutical companies are developing Seborrhoeic Dermatitis treatments?
Which of these firms’ pharmaceuticals is the most widely used?
How many Seborrhoeic Dermatitis medications is each company producing?
How many drugs for Seborrheic Dermatitis are in the early, mid, or late stages of development?
How many of the current therapies under development can be used alone or in combination with other treatments?
What are the essential industry-industry and industry-academy collaborations, mergers and acquisitions, and licensing practices affecting seborrhoeic dermatitis?
Related Reports
Sebohrrea Pipeline Insights
Get a comprehensive analysis of Sebohrrea pipeline therapies and key companies, including Arcutis Biotherapeutics, Cutanea Life Sciences Inc., Vyome Therapeutics, among others.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/